1-3 of 3
Youssef Hijazi
Close
Sort by
Journal Articles

Phase 1/2 Study in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Receiving Blinatumomab Treatment

Arend von Stackelberg, Franco Locatelli, Gerhard Zugmaier, Rupert Handgretinger, Tanya M. Trippett, Carmelo Rizzari, Christian M. Zwaan, Deepa Bhojwani, Steven G. Dubois, MD, Peter Bader, Arndt Borkhardt, Maureen O'Brien, Susan R. Rheingold, MD, Todd Michael Cooper, Kuolung Hu, Noemi Mergen, Anja Fischer, Min Zhu, Youssef Hijazi, James Whitlock, Lia Gore
Journal: Blood
Blood (2014) 124 (21): 2292.
https://doi.org/10.1182/blood.V124.21.2292.2292
Published: 2014
Journal Articles

A Phase 1/2 Study Of Blinatumomab In Pediatric Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Arend von Stackelberg, Gerhard Zugmaier, Rupert Handgretinger, Franco Locatelli, Carmelo Rizzari, Tanya M. Trippett, Arndt Borkhardt, MD, Susan R. Rheingold, Peter Bader, Deepa Bhojwani, MD, Todd Michael Cooper, Steven G. DuBois, Maureen M. O'Brien, MD, Christian M. Zwaan, Chris Holland, Noemi Mergen, Anja Fischer, Min Zhu, Youssef Hijazi, James Whitlock, Lia Gore, MD
Journal: Blood
Blood (2013) 122 (21): 70.
https://doi.org/10.1182/blood.V122.21.70.70
Published: 2013
Journal Articles

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Clinical Trials & Observations
Matthias Klinger, Christian Brandl, Gerhard Zugmaier, Youssef Hijazi, Ralf C. Bargou, Max S. Topp, Nicola Gökbuget, Svenja Neumann, Mariele Goebeler, Andreas Viardot, Matthias Stelljes, Monika Brüggemann, Dieter Hoelzer, Evelyn Degenhard, Dirk Nagorsen, Patrick A. Baeuerle, Andreas Wolf, Peter Kufer
Journal: Blood
Blood (2012) 119 (26): 6226–6233.
https://doi.org/10.1182/blood-2012-01-400515
Published: 2012
Includes: Supplemental data